Group 1: Investor Relations Activity Overview - The investor relations activity was categorized as a specific object survey [1] - The event took place on September 26, 2024, at the company's first-floor conference room [2] - Attendees included representatives from Shenwan Hongyuan Securities, Huatai-PineBridge Fund, and Guotou Securities [2] Group 2: CDMO Business Insights - The company's CDMO business is operated by its subsidiary, Hangzhou Xiaobei Technology Co., with a laboratory area of over 2,000 square meters and a team of over 40 members [3][4] - The subsidiary provides one-stop services for small molecule innovative drug clinical intermediates and RSM process quality research to commercial production [4] Group 3: Joint Venture with South Korea - The company established a joint venture, Anhui Chaiyi Dashan Pharmaceutical Co., Ltd., with a registered capital of RMB 100 million, where the company contributed RMB 70 million (70% share) and Dashan contributed RMB 30 million (30% share) [5] - The joint venture focuses on the production and sales of cardiovascular drug formulations, leveraging advantages in the South Korean and Southeast Asian markets [5] Group 4: Product Profitability and Development - Different product categories exhibit varying gross profit margins based on customer type, product variety, and order quantity [6] - Japanese clients typically place orders every six months, while overseas clients may have annual orders [6] - New product development is driven by customer demand or the identification of promising products in the market [6]
峆一药业(430478) - 关于投资者关系活动记录表的公告